Condition: Breast Cancer · Sponsor: Novartis Pharmaceuticals
This is a prospective, multicenter, open-label, non-comparative, non-interventional, observational study to assess te safety and effectiveness of Piqray in the real-world setting
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Cheonan Si, Chungcheongnam-do, South Korea | Recruiting |
| Novartis Investigative Site | Daegu, Dalseo gu, South Korea | Recruiting |
| Novartis Investigative Site | Goyang-si, Gyeonggi-do, South Korea | Recruiting |
| Novartis Investigative Site | Suwon, Gyeonggi-do, South Korea | Recruiting |
| Novartis Investigative Site | Gyeonggi-do, Korea, South Korea | Recruiting |
| Novartis Investigative Site | Seoul, Korea, South Korea | Recruiting |
| Novartis Investigative Site | Seoul, Seoul, South Korea | Completed |
| Novartis Investigative Site | Seoul, Seoul, South Korea | Recruiting |
| Novartis Investigative Site | Seoul, Yangcheon gu, South Korea | Recruiting |
| Novartis Investigative Site | Busan, South Korea | Recruiting |
| Novartis Investigative Site | Busan, South Korea | Recruiting |
| Novartis Investigative Site | Daegu, South Korea | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05293470